Meiji Yasuda Asset Management Co Ltd. Increases Stock Holdings in Elevance Health, Inc. $ELV

Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Elevance Health, Inc. (NYSE:ELV) by 145.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,004 shares of the company’s stock after acquiring an additional 3,562 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Elevance Health were worth $2,105,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ELV. Artisan Partners Limited Partnership boosted its holdings in Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after acquiring an additional 901,626 shares during the period. First Eagle Investment Management LLC boosted its holdings in Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after acquiring an additional 798,457 shares during the period. Brave Warrior Advisors LLC boosted its holdings in Elevance Health by 65.3% during the 3rd quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock valued at $592,603,000 after acquiring an additional 724,349 shares during the period. Baupost Group LLC MA boosted its holdings in Elevance Health by 114.1% during the 3rd quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock valued at $426,195,000 after acquiring an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its holdings in Elevance Health by 44.2% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock valued at $660,935,000 after acquiring an additional 627,038 shares during the period. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ELV has been the subject of a number of research analyst reports. UBS Group raised their target price on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Robert W. Baird raised their target price on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Evercore reaffirmed a “hold” rating on shares of Elevance Health in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and increased their price target for the company from $363.00 to $498.00 in a research report on Wednesday. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $399.32.

Elevance Health Trading Up 1.2%

NYSE:ELV opened at $394.41 on Friday. The stock’s 50 day moving average price is $333.81 and its 200 day moving average price is $336.25. The company has a market capitalization of $85.65 billion, a PE ratio of 16.78, a P/E/G ratio of 2.21 and a beta of 0.66. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $408.00.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts anticipate that Elevance Health, Inc. will post 26.91 EPS for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.